Effective July 1, 2021, the Coagulation Department within the Spectrum Health Regional Laboratory will go live with an in-house, bovine based, Chromogenic Factor VIII assay.
This assay, a photometric determination of Factor VIII activity, is useful for monitoring coagulation factor replacement therapy of selected extended half-life coagulation factor replacements and Emicizumab therapy, a recombinant, monoclonal antibody that restores the function of the missing activated factor VIII by bridging FIXa and FX. The action of Emicizumab interferes with all APTT clot based and human chromogenic based assays, leading to an overestimation of Factor VIII activity. As such, the bovine based Chromogenic Factor VIII assay is recommended. The Chromogenic Factor VIII activity also assists in the diagnosis of hemophilia A using a 2-stage assay, particularly when the 1-stage clot based assay is normal.
For questions about this test, please refer to the laboratory catalog or use the Contact Us link above.
Chromogenic Factor VIII Activity – Epic Code: LAB1230831 | Interface Code: 1230831 | CPT: 85240
Effective January 26, 2021, the reference range for the Gestational Diabetes 1 Hour Screen will be updated from 65-140 to 65-135. This reference range adjustment is being made to better align with the current practices of our OB/GYN providers for abnormal flagging for gestational diabetes.
UPDATED 6/3/2020 – This test has been put on hold until further notice. Spectrum Health Laboratory will continue to forward orders for Noninvasive Prenatal Screening to Natera to perform the testing.
As of November 25th 2019 the following tests for Herpes Simplex Virus (HSV) IgM antibody testing will be obsoleted.
Herpes IgM Antibody Screen – LAB3576
Herpes Simplex Virus (HSV) Antibody Screen, IgM, by EIA, Serum – LAB3578
Herpes Simplex Panel – LAB1230539
Effective November 5th, testing for Beta-2 Glycoprotein 1 antibodies (IgG and IgM, serum) will change from a reference send out test to Mayo Medical Laboratories to an in-house test available at Spectrum Health Laboratories. This testing is useful for evaluation of patients of suspected antiphospholipid antibody syndrome.
In addition, a new Antiphospholipid Antibody Syndrome Panel will be added which allows for appropriate and complete testing for antiphospholipid antibody syndrome. This panel includes:
Cardiolipin IgG and IgM Antibodies
Beta-2 Glycoprotein 1 IgG and IgM Antibodies
Beginning February 21st 2017, Spectrum Health Regional Laboratory is proud to announce that Cardiolipin IgG/IgM antibody testing will now be performed in-house as discriminatory testing. The tests can be ordered separately or in combination (see New Test Information below).